Apellis Pharmaceuticals (NASDAQ:APLS) said early Thursday that a total of ten cases of retinal vasculitis have been confirmed with two more suspected among recipients of its eye medication Syfovre.
X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback